Hypha Labs（FUNI）株式概要Hypha Labs, Inc.は、米国でバイオリアクターの研究、開発、商業化に従事している。 詳細FUNI ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間15.5%減少しました。 マイナスの株主資本 収益が 100 万ドル未満 ( $0 )+3 さらなるリスクすべてのリスクチェックを見るFUNI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.014該当なし内在価値ディスカウントEst. Revenue$PastFuture-3m3m2016201920222025202620282031Revenue US$0.0003Earnings US$0.00002AdvancedSet Fair ValueView all narrativesHypha Labs, Inc. 競合他社Fenbo HoldingsSymbol: NasdaqCM:FEBOMarket cap: US$11.1mAterianSymbol: NasdaqCM:ATERMarket cap: US$11.1mViomi TechnologySymbol: NasdaqGS:VIOTMarket cap: US$60.7mLuvu BrandsSymbol: OTCPK:LUVUMarket cap: US$2.4m価格と性能株価の高値、安値、推移の概要Hypha Labs過去の株価現在の株価US$0.01452週高値US$0.0452週安値US$0.0053ベータ1.671ヶ月の変化-45.06%3ヶ月変化-53.82%1年変化-50.18%3年間の変化98.57%5年間の変化-72.20%IPOからの変化-99.86%最新ニュースお知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.お知らせ • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.お知らせ • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.お知らせ • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.お知らせ • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.株主還元FUNIUS Consumer DurablesUS 市場7D-14.7%5.2%1.2%1Y-50.2%8.4%28.7%株主還元を見る業界別リターン: FUNI過去 1 年間で8.4 % の収益を上げたUS Consumer Durables業界を下回りました。リターン対市場: FUNIは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is FUNI's price volatile compared to industry and market?FUNI volatilityFUNI Average Weekly Movement38.7%Consumer Durables Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: FUNIの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: FUNIの 週次ボラティリティ は、過去 1 年間で23%から39%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト20105A. Douglasshyphalabs.com米国でバイオリアクターの研究、開発、商品化に従事。同社が提供するHypha Micropearlバイオリアクターは、食用に適したキノコの生産を促進するために設計された家庭用機器である。同社は2010年に法人化され、ネバダ州ラスベガスに本社を置いている。もっと見るHypha Labs, Inc. 基礎のまとめHypha Labs の収益と売上を時価総額と比較するとどうか。FUNI 基礎統計学時価総額US$2.28m収益（TTM）-US$2.16m売上高(TTM)n/a0.0xP/Sレシオ-1.1xPER（株価収益率FUNI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計FUNI 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$2.16m収益-US$2.16m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.013グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-64.7%FUNI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 19:43終値2026/05/22 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hypha Labs, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095
お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095
お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.
お知らせ • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.
お知らせ • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.
お知らせ • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.
お知らせ • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.
